Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease.

Autor: Janelidze S; Clinical Memory Research Unit, Lund University, Sölvegatan 18, Lund, Sweden. shorena.janelidze@med.lu.se., Stomrud E; Clinical Memory Research Unit, Lund University, Sölvegatan 18, Lund, Sweden., Smith R; Clinical Memory Research Unit, Lund University, Sölvegatan 18, Lund, Sweden.; Department of Neurology, Skåne University Hospital, Entrégatan 7, 222 42, Lund, Sweden., Palmqvist S; Clinical Memory Research Unit, Lund University, Sölvegatan 18, Lund, Sweden.; Department of Neurology, Skåne University Hospital, Entrégatan 7, 222 42, Lund, Sweden., Mattsson N; Clinical Memory Research Unit, Lund University, Sölvegatan 18, Lund, Sweden.; Department of Neurology, Skåne University Hospital, Entrégatan 7, 222 42, Lund, Sweden.; Wallenberg Center for Molecular Medicine, Lund University, Klinikgatan 32, 221 84, Lund, Sweden., Airey DC; Eli Lilly and Company, Indianapolis, IN, 46285, USA., Proctor NK; Eli Lilly and Company, Indianapolis, IN, 46285, USA., Chai X; Eli Lilly and Company, Indianapolis, IN, 46285, USA., Shcherbinin S; Eli Lilly and Company, Indianapolis, IN, 46285, USA., Sims JR; Eli Lilly and Company, Indianapolis, IN, 46285, USA., Triana-Baltzer G; Neuroscience Biomarkers, Janssen Research & Development, 3210 Merryfield Row, San Diego, CA, CA 92121, USA., Theunis C; Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium., Slemmon R; Neuroscience Biomarkers, Janssen Research & Development, 3210 Merryfield Row, San Diego, CA, CA 92121, USA., Mercken M; Janssen Pharmaceutical Companies of Johnson & Johnson, Turnhoutseweg 30, 2340, Beerse, Belgium., Kolb H; Neuroscience Biomarkers, Janssen Research & Development, 3210 Merryfield Row, San Diego, CA, CA 92121, USA. HKolb1@ITS.jnj.com., Dage JL; Eli Lilly and Company, Indianapolis, IN, 46285, USA. Jeffrey.Dage@Lilly.com., Hansson O; Clinical Memory Research Unit, Lund University, Sölvegatan 18, Lund, Sweden. Oskar.Hansson@med.lu.se.; Memory Clinic, Skåne University Hospital, Simrisbanvägen 14, 205 02, Malmö, Sweden. Oskar.Hansson@med.lu.se.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2020 Apr 03; Vol. 11 (1), pp. 1683. Date of Electronic Publication: 2020 Apr 03.
DOI: 10.1038/s41467-020-15436-0
Abstrakt: Cerebrospinal fluid (CSF) p-tau181 (tau phosphorylated at threonine 181) is an established biomarker of Alzheimer's disease (AD), reflecting abnormal tau metabolism in the brain. Here we investigate the performance of CSF p-tau217 as a biomarker of AD in comparison to p-tau181. In the Swedish BioFINDER cohort (n = 194), p-tau217 shows stronger correlations with the tau positron emission tomography (PET) tracer [ 18 F]flortaucipir, and more accurately identifies individuals with abnormally increased [ 18 F]flortaucipir retention. Furthermore, longitudinal increases in p-tau217 are higher compared to p-tau181 and better correlate with [ 18 F]flortaucipir uptake. P-tau217 correlates better than p-tau181 with CSF and PET measures of neocortical amyloid-β burden and more accurately distinguishes AD dementia from non-AD neurodegenerative disorders. Higher correlations between p-tau217 and [ 18 F]flortaucipir are corroborated in an independent EXPEDITION3 trial cohort (n = 32). The main results are validated using a different p-tau217 immunoassay. These findings suggest that p-tau217 might be more useful than p-tau181 in the diagnostic work up of AD.
Databáze: MEDLINE
Externí odkaz: